Company / SG&A per Share
NovaBay Pharmaceuticals, Inc. SG&A per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$1.51
FY2024
5-year range
$0.17 / $3.68
FY2020-FY2024
Trend
+211.4%
vs FY2023
Sector context
#96 of 208
Health Care
What the data says
SG&A per Share changed +211% YoY in FY2024, a notable deviation from the 9-year average annual change of +222%.
Based on SEC 10-K filings.
1.51 in FY2024 with a 5-year CAGR of +43.8%.
Improved from $3.68 to $1.51 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +108.8%
- 5-Year CAGR
- +43.8%
- 10-Year CAGR
- -
Sector benchmark
#113 of 208 in Health CareTop 54% of 208This company $1.51 Sector average $29.78
▼
-94.9% below sector average
Key checks
Key Insights
- In FY2024, sg&a per share increased 211.4% year-over-year.
- Ranks #96 out of 208 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2015.
- Lowest sg&a per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.51 | +211.4% |
| FY2023 | $0.49 | -86.8% |
| FY2022 | $3.68 | +2119.1% |
| FY2021 | $0.17 | -1.9% |
| FY2020 | $0.17 | -31.1% |
| FY2019 | $0.25 | -28.2% |
| FY2018 | $0.34 | -39.6% |
| FY2017 | $0.57 | -72.7% |
| FY2016 | $2.08 | -76.3% |
| FY2015 | $8.76 | +4823.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026